The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries
Introduction
The ovaries are common sites of metastasis for malignancies originating in the genital tract and elsewhere. Gastrointestinal tract and breast cancers are the most common nongenital tumors metastatic to the ovaries [1], [2], [3], [4]. While surgical cytoreduction to a low volume of residual tumor is of proven value in primary epithelial ovarian cancer, there is little information on the outcome of patients with tumors metastatic to the ovary who undergo cytoreduction. Some groups have reported that such patients benefit from cytoreduction, but debate continues whether the surgical strategy for primary ovarian cancer should be applied to patients with metastatic disease.
The purpose of this study is to evaluate the clinical characteristics as well as the role of cytoreductive surgery on survivals in patients with metastases to the ovaries from nongenital organs.
Section snippets
Patients and methods
One hundred and fifty-four patients with metastases to the ovary from nongenital organs were identified at Hacettepe University Hospital between 1982 and 2004. Data were obtained from patients' files and pathology reports. Patients' records were reviewed regarding the following parameters: age, gravidity and parity, menopausal status, chief complaint, operative findings, primary site of origin, surgical treatment modalities and survival in months. Primary tumors included breast cancer, stomach
Results
One hundred and fifty-four cases of nongenital tract neoplasms with metastases to the ovary were identified in a period of 22 years in our institute. Nongenital cancers metastatic to the ovary accounted for 9% (154/1700) of all malignant ovarian neoplasms.
The clinical, pathological and intraoperative characteristics of patients are presented in Table 1. The majority of nongenital cancers metastatic to the ovaries originated from gastrointestinal tract, especially from stomach and colon (23% and
Discussion
Metastasis to the ovary from genital and nongenital neoplasms is not uncommon and its incidence reaches up to 40% in autopsy series [5]. Generally, these rates include both genital and nongenital neoplasms. In our institute, 9% of patients undergoing surgery for an ovarian malignancy had a primary carcinoma of a nongenital site.
The most common primary site was the gastrointestinal tract, especially the stomach and colon and the most common single organ was breast as consistent with other
References (22)
- et al.
Incidence of metastasis to the ovaries from nongenital tract primary tumors
Gynecol. Oncol.
(2004) - et al.
Nongenital cancers metastatic to the ovary
Gynecol. Oncol.
(1992) - et al.
Ovarian involvement in extragenital cancer
Gynecol. Oncol.
(1989) - et al.
Metastatic ovarian tumors: a review of 64 cases
Gynecol. Oncol.
(2003) - et al.
Colon cancer with metastasis to the ovary at time of initial diagnosis
Gynecol. Oncol.
(1997) - et al.
Retrograde lymphatic spread: a likely route for metastatic ovarian cancers of gastrointestinal origin
Gynecol. Oncol.
(1997) - et al.
Breast cancer metastatic to abdomen and pelvis: role of surgical resection
Gynecol. Oncol.
(2003) - et al.
Prognostic factors of Krukenberg's tumor
Gynecol. Oncol.
(2001) - et al.
Cancer metastatic to the ovary—Factors influencing survival
Obstet. Gynecol.
(1975) - et al.
Malignant tumors metastatic to the ovaries
J. Surg. Oncol.
(1995)
Metastatic tumours of the ovary
Cited by (114)
Effect of metastasectomy on the outcome of patients with ovarian metastasis of colorectal cancer: A systematic review and meta-analysis
2023, European Journal of Surgical OncologyAppendiceal tumours and pseudomyxoma peritonei: Literature review with PSOGI/EURACAN clinical practice guidelines for diagnosis and treatment
2021, European Journal of Surgical OncologySubjective assessment and IOTA ADNEX model in evaluation of adnexal masses in patients with history of breast cancer
2023, Ultrasound in Obstetrics and GynecologyKrukenberg tumors
2023, Ovarian Cancer: The "ynaecological Challenge" from Diagnostic Work-Up to Cytoreduction and Chemotherapy. Volume 1